Acarix CADScor®System multi-center trial confirms previous preliminary results of CADScor®System ruling out CAD with 97% negative predictive value
Malmö. Sweden, March 17, 2017. Acarix AB (publ) (“Acarix” or the “Company”) today announced the results from a new multi-center trial of its handheld CADScor®System for non-invasive, non-radiation acoustic detection of Coronary Artery Disease (“CAD”). The results are presented at the American College of Cardiology 2017 Annual Scientific Meeting held in Washington on 17-19 March 2017 and showed that the handheld CADScor®System rules out CAD with 97% negative predictive value. The results confirm the Company’s previously announced figures which, prior to this study, was unconfirmed.The trial